Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics of the patients, by adverse event severity grading

From: Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study

  Adverse events by severity grading (N = 51)
  Moderate-to-severe events (n = 26) Mild events (n = 25) P-value
Gender: Male, n (%) 16 (61.5%) 15 (60.0%) 0.91
Age: mean ± SD, yrs 34.1 ± 8.3 35.0 ± 10.2 0.71
Weight: mean ± SD, kg 51.4 ± 10.3 53.9 ± 12.3 0.45
HIV co- infection, n (%) 18 (69.2%) 10 (40%) 0.04
HAART, n (%) 5 (19.2%) 7 (28%) 0.46
Duration (days) of therapy; median (IQR) 183.5 (173–243) 185 (175.5-212) 0.81
Number of drugs in intensive phase regimen; median (IQR) 5 (5–6) 5 (5–6) 0.61
  1. SD = standard deviation; yrs = years; kg = kilogrammes; HIV = human immunodeficiency virus; HAART = highly active antiretroviral therapy; TB = tuberculosis; IQR = interquartile range.